Early cancer diagnoses reach record level in NHS
pharmaphorum
JANUARY 2, 2025
Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.
Thu.Jan 02, 2025
105 
10 clinical trials to watch in the first half of 2025
Bio Pharma Dive
JANUARY 2, 2025
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Artificial intelligence and atopic dermatitis: A new era for disease management?
Pharmaceutical Technology
JANUARY 2, 2025
Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.
Neumora plummets on depression drug data
Bio Pharma Dive
JANUARY 2, 2025
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Tirzepatide outpacing Wegovy in the obesity space
Pharmaceutical Technology
JANUARY 2, 2025
Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
Bio Pharma Dive
JANUARY 2, 2025
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end of recent annual tallies.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Bio Pharma Dive
JANUARY 2, 2025
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.
Neumora shares sink following Phase III flop in MDD
Pharmaceutical Technology
JANUARY 2, 2025
The Phase III KOASTAL-1 study with Neumoras lead asset navacaprant failed to meet its primary and secondary endpoint.
Anteris IPO Helps Bring Minimally Invasive Heart Valve Innovations
XTalks
JANUARY 2, 2025
Anteris Technologies Global Corp. (ATGC) has gone public with its initial public offering (IPO), marking a significant milestone in its journey to transform the heart valve market. The company offered 14.8 million shares of its common stock at an initial price of $6.00 per share. Trading began on the Nasdaq Global Market on December 13, 2024, under the ticker symbol “AVR,” with the offering closed on December 16, 2024.
UK MHRA approves MSD’s pulmonary arterial hypertension therapy
Pharmaceutical Technology
JANUARY 2, 2025
MSD has received the UK MHRA approval for sotatercept, marketed as Winrevair, to treat PAH in the adult population.
EC approves Rybrevant with Lazcluze for advanced lung cancer
Pharma Times
JANUARY 2, 2025
New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC
HUTCHMED to divest 45% equity interest in SHPL for $608m
Pharmaceutical Technology
JANUARY 2, 2025
HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL)
UK regulator warns against buying weight-loss medicines without prescription
Pharma Times
JANUARY 2, 2025
MHRA urges caution over illegal medicines from beauty salons and social media
The unmet need in T2-low asthma: A critical gap in treatment
Pharmaceutical Technology
JANUARY 2, 2025
Severe asthma is traditionally classified into either high or low T-helper cell type 2 (T2) subtypes.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Neumora laid low by depression trial failure
pharmaphorum
JANUARY 2, 2025
The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price
Innovent and Roche link on lung cancer therapy development
Pharmaceutical Technology
JANUARY 2, 2025
Innovent and Roche have entered a partnership and exclusive licence agreement to accelerate the development of IBI3009.
Roche licenses Innovent ADC that could challenge Amgen drug
pharmaphorum
JANUARY 2, 2025
Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market
Trade & Channel Strategies 2024: Empowering Women in Pharma Trade
Pharmaceutical Commerce
JANUARY 2, 2025
Lisa Arthurs, VP, trade, Two Labs, discusses a roundtable discussing women in trade as well as empowering future leaders.
Flagship-backed AI startup Valo shelves eye disease drug
pharmaphorum
JANUARY 2, 2025
Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug
The Connection Between Physician Engagement and Tackling Health-Related Social Needs
Pharmaceutical Commerce
JANUARY 2, 2025
Is this level of involvement with HRSNs associated with higher burnout?
Hutchmed cashes in a Chinese JV to help fund its pipeline
pharmaphorum
JANUARY 2, 2025
Hutchmed has agreed to divest its share of a non-core Chinese JV through a pair of deals that will give it a cash injection to plough into R&D.
A Common Sleeping Pill May Reduce The Buildup of Alzheimer’s Proteins, Study Finds
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 2, 2025
(Tero Vesalainen/iStock/Getty Images) There’s still so much we don’t know about Alzheimer’s disease, but the link between poor sleep and worsening disease is one that researchers are exploring with gusto.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Triumphing in trials
pharmaphorum
JANUARY 2, 2025
The challenges facing oncology clinical trials are multifaceted, but there is a clear opportunity for pharmaceutical companies to rethink their approach to clinical research, and prioritise the patient from the beginning.
Parliamentary panel asks NPPA to submit detailed note on 50% price hike on 11 drugs
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 2, 2025
A Parliamentary panel has sought the National Pharmaceutical Pricing Authority (NPPA) to submit a detailed note on the recent decision by the government to increase the prices on 11 drug formulations by 50 per cent.
Health In Tech IPO Fuels AI-Driven Health Coverage for Small Businesses
XTalks
JANUARY 2, 2025
Health In Tech ( NASDAQ: HIT ), a leader in the Insurtech space, has successfully raised $9.2 million in its initial public offering (IPO) to fuel its innovative platform. Insurtech , which is the use of technology to innovate and improve the insurance industry, leverages AI, big data, machine learning and more to automate processes, reduce administrative costs and enhance risk assessment accuracy.
FDA’s Final Rule on the Implied Nutrient Content Claim “Healthy” Maintains Focus on Foods Rather than on Nutrients
FDA Law Blog
JANUARY 2, 2025
By Ritte van Laack As we previously reported in 2022, FDA published a proposed rule defining the nutrient content claim healthy. The proposed revised rule constituted a radical change from the original definition of healthy, which focused on the presence of individual (beneficial) nutrients. In contrast, the 2022 proposed redefinition focused on food groups recommended by nutrition science and the Dietary Guidelines (DGs), 2020-2025.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Top 10 Best-Selling Immunology Drugs by Recent Sales Data
XTalks
JANUARY 2, 2025
The immunology drug market is a dynamic landscape driven by innovation, expanded indications and competitive strategies. From biologics to biosimilars, the top-performing drugs in this sector not only offer life-changing therapies for patients but also generate billions in revenue for pharmaceutical companies. This blog delves into the top 10 best-selling immunology drugs based on recent sales data from 2023, spotlighting their therapeutic applications, pricing and market strategies.
Innovative approaches to improving drug discovery
Drug Discovery World podcast
JANUARY 2, 2025
This is the latest episode of the free DDW narrated podcast, titled Innovative approaches to improving drug discovery, which covers three articles written for DDW Volume 24 Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development? , Sitting Down With Dr Harren Jhoti, Astex Pharmaceuticals , and The Nobel Prize winning power of click chemistry.
In Response to Current Economic Pressures, Which Cost Optimization Strategy Is Your Company Implementing?
XTalks
JANUARY 2, 2025
Economic pressures are prompting companies across the life sciences industry to focus on the right cost optimization strategy to maintain productivity and innovation. From reevaluating pipelines to investing in efficiency-boosting technologies, organizations are finding creative ways to reduce expenses while staying competitive. Take part in our poll to share which strategies your company is implementing to navigate these challenges and shape a sustainable path forward.
Let's personalize your content